Nanoparticulate Mediated Transcutaneous Immunization: Myth or Reality

Overview

Journal Nanomedicine

Publisher Elsevier

Specialties Biomedical Engineering
Biotechnology

Date 2016 Jan 16

PMID 26767517

Citations 10

Authors

Monika Kaurav

Sunita Minz

Kantrol Sahu

Manoj Kumar

Jitender Madan

Ravi Shankar Pandey

Affiliations

Soon will be listed here.

Abstract

From The Clinical Editor: Transcutaneous immunization has been investigated by many as a promising route of vaccination. In this comprehensive review article, the authors described and discussed the existing knowledge and difficulties in this approach. Furthermore, ways of improving transcutaneous delivery were also reviewed.

Citing Articles

Overcoming Skin Barrier with Transfersomes: Opportunities, Challenges, and Applications.

Dixena B, Madhariya R, Panday A, Ram A, Jain A Curr Drug Deliv. 2024; 22(2):160-180.

PMID: 38178667 DOI: 10.2174/0115672018272012231213100535.

Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.

Hartmann A, Bartneck J, Pielenhofer J, Meiser S, Arnold-Schild D, Klein M Front Immunol. 2023; 14:1238861.

PMID: 37727790 PMC: 10505723. DOI: 10.3389/fimmu.2023.1238861.

Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects.

Gupta M, Wahi A, Sharma P, Nagpal R, Raina N, Kaurav M Vaccines (Basel). 2022; 10(12).

PMID: 36560420 PMC: 9788126. DOI: 10.3390/vaccines10122011.

Microneedle-based two-step transdermal delivery of Langerhans cell-targeting immunoliposomes induces a Th1-biased immune response.

Yu Y, Wang H, Guo B, Wang B, Wan Z, Zhang Y Eur J Pharm Biopharm. 2022; 177:68-80.

PMID: 35716853 PMC: 9197786. DOI: 10.1016/j.ejpb.2022.06.004.

Public health risks associated with hepatitis E virus (HEV) as a food-borne pathogen.

Ricci A, Allende A, Bolton D, Chemaly M, Davies R, Fernandez Escamez P EFSA J. 2020; 15(7):e04886.

PMID: 32625551 PMC: 7010180. DOI: 10.2903/j.efsa.2017.4886.